Kiaco, KinangaRodrigues, António Sebastiãodo Rosário, VirgílioGil, José PedroLopes, Dinora2018-05-102018-05-102017-09-21PURE: 3180599PURE UUID: 0b90a419-ea77-4894-9190-6e1b2641b203PubMed: 28934955PubMedCentral: PMC5609073Scopus: 85029673999http://hdl.handle.net/10362/36450Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.6821184engAngolaArtemether-lumefantrineCYP450Human polymorphismMDR1SDG 3 - Good Health and Well-beingjournal article10.1186/s12936-017-2006-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609073/